Galena Left To Hope Review Of Trial Operations Rescues NeuVax
Cancer vaccine development is a tricky undertaking, but Galena may be grasping at last straws with a third-party review of a recently halted study of NeuVax, hoping to discover operational reasons for cancer vaccine's poor performance.
You may also be interested in...
Preparing to meet with FDA in December to plan next steps for NeuVax in triple-negative breast cancer, Sellas reveals 26-month data that show further clinical benefit compared with a 19-month interim look. Firm still hopes to out-license the vaccine candidate.
Sellas is pursuing accelerated approval for NeuVax in triple-negative breast cancer based on Phase II data, but that may be a tough sell with the FDA.
Pivotal and Biomatics launch new VC funds totaling $300m and $200m, respectively; Spero raises a $51.7m Series C round; BeyondSpring is March's only US IPO, so far; Aurinia and TG Therapeutics capitalize on positive data with secondary offerings; and Galena hires a "strategic review" advisor.